NCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting
Bristol-Myers Squibb
Hoffmann-La Roche
Indiana University
University of Pennsylvania
Novartis
Boston Medical Center
VA Office of Research and Development